Sphera Funds Management’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Sphera Funds Management’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-502,936	Closed	-$5.05M	–	124
2023 Q4	$5.05M	Sell	502,936 -1,028,561	-67%	-$4.67M	0.81%	46
2023 Q3	$4.41M	Buy	1,531,497 +302,832	+25%	+$1.11M	0.8%	44
2023 Q2	$4.68M	Sell	1,228,665 -1,131,915	-48%	-$3.17M	0.73%	54
2023 Q1	$4.39M	Buy	+2,360,580	New	+$4.93M	0.73%	48
2021 Q3	–	Sell	-233,850	Closed	-$3.04M	–	160
2021 Q2	$3.04M	Buy	233,850 +21,250	+10%	+$285K	0.21%	90
2021 Q1	$3.27M	Buy	+212,600	New	+$5.02M	0.25%	90

Sphera Funds Management's GRCL Position: Q1 2024 in Review

Sphera Funds Management sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 502,936 shares — an estimated $5.05M sold.

Sphera Funds Management first reported a position in GRCL in Q1 2021 and held it in 6 quarters. The position peaked at $5.05M in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Sphera Funds Management reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Sphera Funds Management sold 502,936 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $5.05M.
Sphera Funds Management first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2021 and held it in 6 quarters.
Sphera Funds Management's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $5.05M in Q4 2023.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Sphera Funds Management's 13F filing for Q1 2024, filed 15 May 2024.